Evidence map›Paper›PMID 35411483›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Deep Brain Stimulation for Addictive Disorders-Where Are We Now?

Jason Yuen, Abbas Z Kouzani, Michael Berk, Susannah J Tye, Aaron E Rusheen, Charles D Blaha, Kevin E Bennet, Kendall H Lee, Hojin Shin, Jee Hyun Kim and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Neuromodulation of the central nervous system for facial pain.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Physical Therapy for Addiction.Advances in experimental medicine and biology · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jason YuenDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-6988-388X
Abbas Z KouzaniSchool of Engineering, Deakin University, Geelong VIC 3216, Australia.
Michael BerkDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong VIC 3216, Australia.
Susannah J TyeQueensland Brain Institute, The University of Queensland, St Lucia, QLD, 4072, Australia.
Aaron E RusheenDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Charles D BlahaDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Kevin E BennetDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Kendall H LeeDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Hojin ShinDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Jee Hyun KimDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong VIC 3216, Australia. drjeehyunkim@gmail.com.
Yoonbae OhDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA. oh.yoonbae@mayo.edu.
Mayo Clinic · USDeakin University · AUUniversity of Minnesota · US

Funding

TRAINING IN TRANSLATIONAL RESEARCH: BENCH TO BEDSIDER25GM055252 · NIGMS · MAYO CLINIC ROCHESTER · PI LUJAN, LUIS, MAHER, LOUIS JAMES · 1996 to 2022
$8.3M
NRSA Training CoreTL1TR002380 · NCATS · MAYO CLINIC ROCHESTER · PI Felicity T. B. Enders, ANTHONY John WINDEBANK · 2017 to 2026
$6.0M
Development of advanced voltammetric method for basal neurotransmitter level measurementR01NS112176 · NINDS · MAYO CLINIC ROCHESTER · PI LEE, KENDALL H., OH, YOONBAE · 2019 to 2022
$1.4M
Mechanism of CMPf Deep Brain Stimulation for Tourette SyndromeF31NS115202 · NINDS · MAYO CLINIC ROCHESTER · PI RUSHEEN, AARON ELLIOTT · 2020 to 2023
$195k
NCATS NIH HHS TL1 TR002380NIGMS NIH HHS R25 GM055252NINDS NIH HHS F31 NS115202NINDS NIH HHS R01 NS112176
6 · The paper itself

Abstract

In the face of a global epidemic of drug addiction, neglecting to develop new effective therapies will perpetuate the staggering human and economic costs of substance use. This review aims to summarize and evaluate the preclinical and clinical studies of deep brain stimulation (DBS) as a novel therapy for refractory addiction, in hopes to engage and inform future research in this promising novel treatment avenue. An electronic database search (MEDLINE, EMBASE, Cochrane library) was performed using keywords and predefined inclusion criteria between 1974 and 6/18/2021 (registered on Open Science Registry). Selected articles were reviewed in full text and key details were summarized and analyzed to understand DBS' therapeutic potential and possible mechanisms of action. The search yielded 25 animal and 22 human studies. Animal studies showed that DBS of targets such as nucleus accumbens (NAc), insula, and subthalamic nucleus reduces drug use and seeking. All human studies were case series/reports (level 4/5 evidence), mostly targeting the NAc with generally positive outcomes. From the limited evidence in the literature, DBS, particularly of the NAc, appears to be a reasonable last resort option for refractory addictive disorders. We propose that future research in objective electrophysiological (e.g., local field potentials) and neurochemical (e.g., extracellular dopamine levels) biomarkers would assist monitoring the progress of treatment and developing a closed-loop DBS system. Preclinical literature also highlighted the prefrontal cortex as a promising DBS target, which should be explored in human research.

Indexed as

Deep Brain StimulationSubstance-Related DisordersAnimalsDopamineHumansNucleus AccumbensPrefrontal CortexDopamineAddictionAnimal modelsBiomarkersDeep brain stimulationNeuromodulationNeuropsychiatry

Identifiers

PMID35411483
PMCPMC9587163
OpenAlexW4223503363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.